Evidence map›Paper›PMID 40082863›Full record

ArticleBMC medicine2025

Risk, determinants, and persistence of long-COVID in a population-based cohort study in Catalonia.

Manolis Kogevinas, Marianna Karachaliou, Ana Espinosa, Susana Iraola-Guzmán, Gemma Castaño-Vinyals, Laura Delgado-Ortiz, Xavier Farré, Natàlia Blay, Neil Pearce, Magda Bosch de Basea and 5 more

Abstract read
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Risk factors for post-COVID-19 condition: A case-control study in municipalities of Paraíba and Rio de Janeiro, Brazil.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Manolis Kogevinas *ISGlobal, Barcelona, Spain. manolis.kogevinas@isglobal.org.
Marianna Karachaliou *ISGlobal, Barcelona, Spain.
Ana EspinosaISGlobal, Barcelona, Spain.
Susana Iraola-GuzmánGenomes for Life-GCAT Lab, CORE Program. Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain.
Gemma Castaño-VinyalsISGlobal, Barcelona, Spain.
Laura Delgado-OrtizISGlobal, Barcelona, Spain.
Xavier FarréGenomes for Life-GCAT Lab, CORE Program. Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain.
Natàlia BlayGenomes for Life-GCAT Lab, CORE Program. Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain.
Neil PearceLondon School of Hygiene and Tropical Medicine, London, UK.
Magda Bosch de BaseaISGlobal, Barcelona, Spain.
Eva Alonso NoguésBanc de Sang I Teixits (BST), Barcelona, Spain.
Carlota DobañoISGlobal, Barcelona, Spain.
Gemma MoncunillISGlobal, Barcelona, Spain.
Rafael de CidGenomes for Life-GCAT Lab, CORE Program. Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain.
Judith Garcia-AymerichISGlobal, Barcelona, Spain.

Funding

European Regional Development Fund 001-P-001647European Social Fund RYC 2020-029886-I/AEI/10.13039/501100011033
6 · The paper itself

Abstract

backgroundLong-COVID has mostly been investigated in clinical settings. We aimed to assess the risk, subtypes, persistence, and determinants of long-COVID in a prospective population-based study of adults with a history of SARS-CoV-2 infection in Catalonia.

methodsWe examined 2764 infected individuals from a population-based cohort (COVICAT) established before the pandemic and followed up three times across the pandemic (2020, 2021, 2023). We assessed immunoglobulin (Ig)G levels against SARS-CoV-2, clinical, vaccination, sociodemographic, and lifestyle factors. Long-COVID risk and subtypes were defined based on participant-reported symptoms and electronic health records. We identified a total of 647 long-COVID cases and compared them with 2117 infected individuals without the condition.

resultsBetween 2021 and 2023, 23% of infected subjects developed long-COVID symptoms. In 56% of long-COVID cases in 2021, symptoms persisted for 2 years. Long-COVID presented clinically in three subtypes, mild neuromuscular, mild respiratory, and severe multi-organ. The latter was associated with persistent long-COVID. Risk was higher among females, participants under 50 years, of low socioeconomic status, severe COVID-19 infection, elevated pre-vaccination IgG levels, obesity, and prior chronic disease, particularly asthma/chronic obstructive pulmonary disease and mental health conditions. A lower risk was associated to pre-infection vaccination, infection after omicron became the dominant variant, higher physical activity levels, and sleeping 6-8 h. Vaccination during the 3 months post-infection was also protective against long-COVID.

conclusionsLong-COVID persisted for up to 2 years in half of the cases, and risk was influenced by multiple factors.

Indexed as

COVID-19AdultAgedCohort StudiesFemaleHumansMaleMiddle AgedProspective StudiesRisk FactorsSARS-CoV-2SpainCOVID-19EpidemiologyExerciseLong-COVIDSARS-CoV-2 antibodiesSleepVaccines

Identifiers

PMID40082863
PMCPMC11907888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.